KDM6A Antibodies

Lysine-specific demethylase 6A (KDM6A)

Histone demethylase that specifically demethylates'Lys- 27' of histone H3, thereby playing a central role in histone code (PubMed:17851529, PubMed:17713478, PubMed:17761849). Demethylates trimethylated and dimethylated although not monomethylated H3'Lys-27' (PubMed:17851529, PubMed:17713478, PubMed:17761849).

Plays a central role in regulation of posterior development, by regulating HOX gene expression (PubMed:17851529). Demethylation of 'Lys-27' of histone H3 is concomitant with methylation of 'Lys-4' of histone H3, and regulates the recruitment of the PRC1 complex and monoubiquitination of histone H2A (PubMed:17761849).

Gene Information

Human
Gene Name:	KDM6A
Uniprot:	O15550
Entrez:	7403

Family

Belongs to:
UTX family

Alternative Names

bA386N14.2 (ubiquitously transcribed X chromosome tetratricopeptide repeatprotein (UTX)); bA386N14.2; DKFZp686A03225; EC 1.14.11; EC 1.14.11.-; Histone demethylase UTX; KABUK2; KDM6A; Lysine (K)specific Demethylase 6A; Lysine (K)-specific Demethylase 6A; MGC141941; ubiquitously transcribed tetratricopeptide repeat protein X-linked; ubiquitously transcribed tetratricopeptide repeat, X chromosome; ubiquitously transcribed TPR protein on the X chromosome; ubiquitously transcribed X chromosome tetratricopeptide repeat protein; ubiquitously-transcribed TPR gene on the X chromosome; Ubiquitously-tra

Molecular Weight

Mass (kDA):
154.177 kDA

Genomic Context

Human
Location:	Xp11.3
Sequence:	X; NC_000023.11 (44873175..45112779)

Subcellular Localizations

Nucleus.

Diseases

• Malignant Neoplasms
• Neoplasms
• Leukemia
• Carcinoma
• Renal Cell Carcinoma
• Kabuki Make-up Syndrome
• Von Hippel-lindau Syndrome
• Cell Transformation, Neoplastic
• Neoplasm Metastasis
• Kidney Neoplasm
• Myeloid Leukemia
• Acute Promyelocytic Leukemia

• Lymphoma
• Medulloblastoma
• Cerebellar Neoplasms
• Congenital Abnormality
• Malignant Paraganglionic Neoplasm
• Leukemia, Myelocytic, Acute
• Pancreatic Neoplasm

Pathways

• Demethylation
• Methylation
• Pathogenesis
• Chromatin Modification
• Cell Development
• Regulation Of Gene Expression
• Histone Modification
• Localization
• Cell Cycle Arrest
• Drug Resistance
• Germ Cell Development
• Reverse Transcription

• Protein Acetylation
• Cell Cycle
• Dna Modification
• Rna Interference
• Chromatin Remodeling
• Oncogenesis

PTMs

• Methylation
• Demethylation

• Phosphorylation
• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KDM6A

Boster Bio Anti-Lysine-Specific Demethylase 6A KDM6A Marker

Are you interested in Boster Bio’s Anti-Lysine Specific Demethylase 6A, KDM6A Marker This article provides information on this antibody, including a list containing common uses, Boster’s high-affinity primary antibodies and typical use scenarios. Continue reading to discover more about the KDM6A Marker. Here are some examples of common uses and applications.

Boster Bio Anti-Lysine-Specific Demethylase 6A, KDM6A Marker

The anti Lysine-specific Demethylacetylase 6A (KDM6A), marker is designed to detect mRNA levels. The marker contains synthetic peptide that is derived from human human lysine specific methylation. The KDM6A mRNA binding protein, Lysine-specific Demethylase Enzyme, recognizes the peptide.

To prepare the anti Lysine-specific Demethylacetylase Antibody, we used a commercially accessible kit (pPLK/GFP+Puro–GASC1 Short Hairpin RNA). We used fresh resected brain glioma tissue to culture. We used sterilized MACS(r), and warmed RPMI/PBS.

Lysine-specific demethylase is a protein which specifically demethylates the Lys-27 portion of histone H3-M. This enzyme is key to the histone cod, as it regulates chromatin remodelling and T-box-dependent gene expression. It also regulates PRC1 and b–catenin recruitment.

This protein has a multitude of functions and is important in the diagnosis of cancer. It is a prosurvival gene that influences ErbB2 tumorigenesis as well as PI-MECs. It also regulates mature keratinocytes' proliferation. It is also involved with cervical cancer differentiation.

The protein was lysed from 2-cell embryos using Laemmli sample buffer containing b-mercaptoethanol and protease inhibitor. After complete lysis, the proteins were separated using SDS-PAGE and transferred to a PVDF membrane. After blocking the membrane for 1 h with 5% skimmilk, the membrane was incubated by rabbit polyclonal and goat anti-rabbit HP-labeled secondary antibodies. This was performed on multiple tissues. After incubation, the membranes were counter stained by Mayor's hemoxylin.

DNp63a contains all four domains. It consists of a DNA binding domain, an oligomerization and transactivation inhibitory domains (TID) and a sterile Alpha motif. The anti-SETDB1 antibody detects the protein with a dilution of 1:200.

Molecular biology and pharmacology have revealed that this protein regulates multiple signalling pathways. Its overexpression inhibits the endogenous repair of damaged cells and angiogenesis after CCSCI. To evaluate the protein's impact on neuronal function and cellular cells, the BBB score was used and IPT scored was used. It regulates multiple pathways, including the Sonic Hedgehog.

Recent research has shown that CCSCI can increase the expression of Xist, EZH2 and other genes. It was possible to determine whether an animal had recovered from endogenous angiogenic injury by using an angled plane test. These results have implications for research in the area of CCSCI. The methyltransferases Xist (and EZH2) are also upregulated following CCSCI.

The SETDB1 genes is found in chromosome segments recurrently amplified by breast cancer. The gene was identified in these cell lines and in primary tumors. Furthermore, it has been implicated in melanoma and lung cancer. It is high in protein expression in breast cancer cells.

Boster provides high-affinity prima antibodies

If you need a highly specific antibody for your work, you can choose one of the primary antibodies offered by Boster Bio. These antibodies are very sensitive and specific. They were validated using 250 tissues. These antibodies are reliable and highly cited, and are tested quantitatively in Western Blotting, Immunohistochemistry, and ELISA to ensure that they will work in your research.

These antibodies are available as either single-molecule or dual-labeled. These antibodies can be used together to allow researchers more questions to be asked using a specimen. Dual labeling gives them more context, and provides robust answers. These antibodies have also been conjugated to various secondary antibodies and reagents, enabling them to recognize a wider variety of target proteins. This combination will allow you to identify specific cells in your studies.

Applications typical

The KDM6A marker is highly specific and a powerful tool to detect cancer cells. This protein is critical for the proliferation, differentiation and maintenance of cancer cells. It also promotes other p53-targeted genes such as Cdkn1a. In addition, KDM6A is involved in demethylase-independent mechanisms that help the p53 tumor suppressor achieve its tumor suppressive activity.

The KDM6A gene is important for the resolution of bivalent genes, which are marked by a single copy of the DNA sequence. KDM6A is less expressed after EMT. It is also suppressed in stem-like populations and TNBCs. The marker removes the H3K27me3 mark that is repressive and maintains basal Ecadherin levels.

The expression pattern of the KDM6A marker in stem cell-enriched subpopulations suggests that this protein plays a selective role in the epithelial setting. KDM6A activity might also explain the increased number of bivalent domains found within HMLETwist cells' genomes. The KDM6A marker can be used to identify recurrent cancers as well as stem cells.

The expression of KDM6A in mouse ES cells has been shown to be regulated by MET. The expression of KDM6A has been associated with reprogramming. Functional and molecular studies have demonstrated that the gene regulates the reprogramming process of mouse ES cells. It is an important initiator during reprogramming. However, the relationship between KDM6Aexpression and MET can be complex.

Female BCa patients with a mutation or low expression of KDM6A genes have poor prognosis. KDM6A may also control sexhormones and contribute to gender-specific diseases. Further research is needed in order to determine the exact function of KDM6A for human cancer. The treatment of this cancer might be more targeted in the event that it is found to decrease in BCa-female patients.

Using the KDM6A marker in mouse models is an effective way to monitor brown adipocyte differentiation. It also inhibits Stat5a's overexpression of other brown fat marker gene genes. Western blots was used to determine the protein level of KDM6A. The data were analyzed by one-way analysis. The results of the experiments were compared with those obtained using a non-targeted marker, which was Stat5a.